Most people treated with radioiodine for Graves' disease experience a predictable dip and rebound in thyroid hormone levels over the first year, while fewer have a rise then fall then rise again, or a steady decline. Temporary fluctuations are the most common outcome.
Claim Context
After radioiodine therapy for Graves' disease, the valley pattern (67%) is the most common trajectory of thyroid hormone change, followed by the mountain pattern (17%) and downhill pattern (16%), suggesting that transient hormone fluctuations are the norm rather than the exception in the first year.
“The late patterns were a stable state after an initial decrease with a bottom followed by an increase (valley pattern) in 47 (67%), a stable state after an initial increase with a peak followed by a decrease with a bottom and a subsequent re-increase (mountain pattern) in 12 (17%) and a late stable state after a gradual slow decrease without an obvious bottom near or till one year (downhill pattern) in 11 (16%).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether these three patterns are consistently observed across different radioiodine dosing practices and global populations.
A systematic review and meta-analysis of all prospective cohort studies reporting the prevalence of valley, mountain, and downhill patterns in Graves' disease patients after radioiodine therapy, including at least 20 studies with standardized hormone measurement protocols. Primary outcome: pooled prevalence estimates for each pattern.
An RCT could test whether altering radioiodine dose or timing of administration changes the prevalence of these patterns.
A double-blind RCT of 300 patients with Graves' disease randomized to low-dose (100–120 MBq), standard-dose (150–180 MBq), or high-dose (200–250 MBq) radioiodine therapy. Primary outcome: proportion developing valley, mountain, or downhill patterns at 12 months.
A prospective cohort could validate the prevalence of these patterns in a larger, more diverse population.
A prospective cohort study of 500 adults with Graves' disease undergoing radioiodine therapy, with monthly thyroid hormone measurements for 12 months. Primary outcome: incidence of valley, mountain, and downhill patterns as defined by the original study criteria.
A case-control study could compare patients with valley pattern vs. those without to identify baseline predictors of pattern development.
A case-control study comparing 100 patients with valley pattern to 100 without (mountain/downhill), matched for age, sex, and radioiodine dose. Exposure: baseline TSH, FT4, TPOAb, and thyroid volume. Primary analysis: odds ratio for valley pattern associated with each baseline factor.
A cross-sectional study could estimate pattern prevalence retrospectively, but cannot confirm temporal sequence.
A cross-sectional analysis of 400 patients with Graves' disease treated with radioiodine therapy 1–2 years prior, grouped by final thyroid status. Retrospective review of available hormone data to classify patterns as valley, mountain, or downhill.